Design Therapeutics (DSGN) FCF Margin (2020)

Design Therapeutics (DSGN) reported FCF Margin of 8660.61% for Q4 2020, up 6.83% sequentially from 9295.0% in Q3 2020.

Design Therapeutics (DSGN) FCF Margin (2020) Analysis & Trends

Design Therapeutics (DSGN) has 1 years of FCF Margin data on file, last reported at 8660.61% in Q4 2020.

For the quarter ending Q4 2020, FCF Margin changed N/A year-over-year to 8660.61%; the trailing twelve-month figure through Dec 2020 stood at 3842.04% (changed N/A YoY), and the FY2020 full-year result was 3869.47%, changed N/A from the prior year.
FCF Margin improved to 8660.61% in Q4 2020, from 9295.0% in the prior quarter.
In the past five years, FCF Margin ranged from a high of 1872.54% in Q1 2020 to a low of 9295.0% in Q3 2020.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	10.45%
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	43.35%
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	23.53%
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Design Therapeutics	725.54 Mn	502.72 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2020	-8,660.61%
Sep 30, 2020	-9,295.00%
Jun 30, 2020	-4,216.13%
Mar 31, 2020	-1,872.54%